An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
Recruiting · Phase 1, Phase 2 · NCT05757141
Conditions: Vanishing White Matter Disease
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Calico Life Sciences LLC
- Tested
- Fosigotifator (drug)
- Dates
- Started 2023-03-13; completion 2035-10
- Results posted
- Not yet
Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.
From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.0M in research payments for this study in 2025 (31 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Florian S. Eichler, MD Neurology · Boston, MA
- Amy Waldman, MD Child Neurology · Philadelphia, PA
- Joshua L. Bonkowsky, MD, PHD Child Neurology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Utah Hospital and Clinics, UT $673,349
- Massachusetts General Hospital, MA $294,890
- Children's Hospital of Philadelphia, PA $45,016
- U of Utah Neuropsychiatric Institute $1,586
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.